Arbutus Biopharma develops therapies aimed at a functional cure for chronic hepatitis B, led by the RNAi candidate imdusiran (AB-729) and complementary agents such as an oral PD-L1 inhibitor. The company focuses on multi-mechanism combinations that suppress the virus, reduce viral antigens, and help restore immune control. It is clinical-stage and builds on earlier work in viral therapeutics and related nucleic-acid delivery intellectual property.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 10.7 | — | 2.5 | — |
| Q3 2025 | 0.5 | — | -7.7 | — |
| Q4 2025 | 1.1 | — | -3.8 | — |
| Q1 2026 | 179.1 | — | 169.7 | — |
| Q2 2026 | 1 | -90.6% | -5.1 | -303.8% |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: MiMedx Group, Inc. (MDXG), Annexon, Inc. (ANNX), Village Super Market, Inc. (VLGEA), Design Therapeutics, Inc. (DSGN), Capital Bancorp, Inc. (CBNK), Priority Technology Holdings, Inc. (PRTH)